Myeloma UK is looking to speak to patients with relapsing myeloma who have received a new combination treatment to help provide evidence in favour of the approval of the treatment in Scotland.
The treatment combination involves two drugs: dexamethasone, a type of steroid, and carfilzomib (Kyprolis®), which is a new proteasome inhibitor that works in a similar way to bortezomib (Velcade®).
This treatment combination, which has only been available through clinical trials, is about to be assessed by Scotland’s drug approval body, the Scottish Medicines Consortium (SMC). Myeloma UK submits evidence to the SMC, making a case for the drug to be approved and made routinely available to patients in Scotland.
We would like to know what patients think about the new treatment combination and how it might compare to treatments that patients currently receive.
What would I need to do?
If you have received carfilzomib and dexamethasone and would be willing to speak with us, we would have a short telephone conversation with you, which would take no longer than 30 minutes. Your views would be anonymised and used to inform our submission to the SMC.
Get in touch
Find out more by contacting our Policy Team on email@example.com or call 0131 557 3332.